Table 2.
Clinical data of cases primarily diagnosed with thymic lymphoma.
| Case | Age (y) | Sex | Size (cm) | Autoimmune Disorders | LESA-like TH | Lymphoma |
|---|---|---|---|---|---|---|
| 1 | 34 | f | n.r. | MALT lymphoma (IgG) | ||
| 2 | 62 | m | >10 | MALT lymphoma (n.m.) | ||
| 3 | 44 | f | 4.0 | present | MALT lymphoma (IgA) | |
| 4 | 72 | f | n.r. | Composite MALT and mantle-cell lymphoma (IgM) | ||
| 5 | 61 | f | n.r. | MALT lymphoma (n.m.) | ||
| 6 | 49 | f | n.r. | MALT lymphoma (n.m.) | ||
| 7 | 75 | m | n.r. | present | MALT lymphoma (n.hcr.) | |
| 8 | 52 | f | 4.5 | MALT lymphoma (IgG) | ||
| 9 | 79 | f | biopsy | MALT lymphoma (n.hcr.) | ||
| 10 | 78 | f | 1.2 | MALT lymphoma (n.hcr.) | ||
| 11 | 63 | f | biopsy | Sjögren syndrome | MALT lymphoma (IgA) |
n.m., no material for additional testing; n.hcr., no heavy chain restriction detectable in immunohistochemistry; n.r., not reported.